Table 1.
Baseline characteristics for participants receiving vehicle-placebo, vehicle-finasteride, TE-placebo, or TE-finasteride
| Variable | Vehicle Placebo | Vehicle Finasteride | TE Placebo | TE Finasteride |
|---|---|---|---|---|
| Age, yr | 70.8 ± 9.7 | 69.5 ± 9.2 | 69.2 ± 8.0 | 64.2 ± 4.8 |
| BMI, kg/m2 | 30.5 ± 3.4 | 28.8 ± 3.9 | 29.5 ± 4.6 | 31.1 ± 2.5 |
| Testosterone, ng/dl | 264 ± 92 | 241 ± 112 | 246 ± 73 | 243 ± 147 |
| BioT, ng/dl | 46 ± 22 | 41 ± 17 | 46 ± 17 | 43 ± 20 |
| DHT, ng/dl | 25 ± 15 | 19 ± 13 | 21 ± 6 | 22 ± 23 |
| RBC, cells/mcl | 4.5 ± 0.5 | 4.7 ± 0.8 | 4.7 ± 0.4 | 4.8 ± 0.4 |
| HCT, % | 40 ± 3.9 | 41 ± 3.9 | 43 ± 3.0 | 42 ± 2.8 |
| HGB, g/dl | 13.5 ± 1.3 | 13.8 ± 1.5 | 14.7 ± 1.4 | 14.6 ± 0.9 |
| Hepcidin, ng/ml | 48 ± 35 | 42 ± 22 | 53 ± 26 | 48 ± 35 |
| Iron, μg/dl | 88 ± 32 | 83 ± 38 | 82 ± 33 | 96 ± 35 |
| Transferrin, μg/dl | 247 ± 37 | 250 ± 25 | 249 ± 31 | 277 ± 36 |
| Transferrin saturation, % | 36 ± 3.3 | 34 ± 4.8 | 34 ± 4.2 | 35 ± 2.89 |
| Ferritin, ng/ml | 142 ± 76 | 154 ± 69 | 186 ± 118 | 222 ± 271 |
Values are means ± SD.
BMI, body mass index; TE, testosterone-enanthate; BioT, bioavailable fractions of testosterone; DHT, dihydrotestosterone; RBC, red blood cells; HCT, hematocrit; HGB, hemoglobin. To convert values for testosterone to nmol/l, multiply by 0.0347. To convert values for DHT to nmol/l, multiply by 0.0344.